Our virtual conference, The PSYCH Symposium is about to begin at Prohibition Partners LIVE and there is still time to join the conversation.
Over the next four days, political, scientific, medical, business and cultural leaders will feature across a range of industry-leading panel discussions.
Only a limited number of places remain to join the international psychedelics community.
Learn MoreSan Francisco senator plans to introduce legislation to decriminalise psychedelics.
Navy SEAL Foundation contributes US$50,000 to psychedelic PTSD study.
Questions posed of Oregon’s new psilocybin therapy program.
Brazil approves esketamine nasal spray to treat patients with severe depression.
New Jersey amends cannabis legalisation bill to downgrade psilocybin penalties.
PharmaTher files a US provisional patent for the use of psilocybin to treat cancer.
MindMed receives approval for a Phase 2a clinical trial to treat adult ADHD with LSD.
NeonMind obtains Health Canada approval to advance psilocybin-based research.
UK’s first psychedelic-assisted therapy clinic is due to open in January 2021.
COMPASS Pathways reports progress in research and development in Q3 2020 results.
Psyched Wellness applies for an up-listing to the QTCQB Venture Marketplace.
Octarine raises US$1.8 million to fund preclinical studies on psychedelic derivatives.
Field Trip Health prepares to enter Oregon’s psilocybin therapy market.
Pilz Bioscience enters into a psilocybin manufacturing agreement.
Silo Wellness announces psychedelic wellness nature retreat in Oregon.
New study shows psilocybin with psychotherapy relieves major depressive symptoms.
Research finds psilocybin increases the expression of neuroplasticity genes in rats.
A four-year study finds that DMT promotes the formation of new neurons in the brain.
Experts debate whether the ‘war on drugs’ is over.